GUIDANT ENROLLS 300 PATIENTS IN DRUG ELUTING STENT PIVOTAL TRIALS AND COMPLETES MANUFACTURING AUDIT

Guidant recently announced that the company has enrolled more than 300 patients in its Spirit II and Spirit III clinical trials, meeting a milestone in the company's exclusive license agreement with Novartis Pharma AG. The company also announced that it has successfully concluded an inspection of its drug eluting stent manufacturing and quality systems at its Temecula site.

Yahoo News (http://biz.yahoo.com/bw/050921/215860.html?.v=1)